In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 1, 2006, Pages 135-138

  Warn, Peter A ^a   Sharp, Andrew ^a   Denning, David W ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Amphotericin B; Antifungal susceptibility; Caspofungin; Itraconazole; Voriconazole

Indexed keywords

1 [3 [4 (4 CYANOPHENYL) 2 THIAZOLYL] 2 (2,5 DIFLUOROPHENYL) 2 HYDROXYBUTYL] 4 [1 [N METHYL N [3 [2 (METHYLAMINO)ACETOXYMETHYL] 2 PYRIDINYL]CARBAMOYLOXY]ETHYL] 1H 1,2,4 TRIAZOL 4 IUM CHLORIDE; 4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES DIFFERENCE;

ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NITRILES; PRODRUGS; PYRIDINES; SOLUBILITY; TRIAZOLES; WATER;

EID: 30344449770     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki399     Document Type: Article

References (13)

1. Groll AH, Kurz M, Schneider W et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999; 42: 431-42.
2. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.
3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
4. Herbrecht R, Denning DW, Patterson T et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002; 347: 408-15.
5. Boyd AE, Modi S, Howard SJ et al. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241-4.
6. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997; 41: 1124-6.
7. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, 2002.
8. Warn PA, Sharp A, Guinea J et al. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother 2004; 53: 743-9.
9. Schmitt-Hoffmann A, Roos B, Spickermann J et al. Multiple ascending dose pharmacokinetics of the new antifungal BAL4815 after intravenous and oral administration of its prodrug BAL8557. In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004. Abstract A-37, p. 9. American Society for Microbiology, Washington, DC, USA.
10. Andes D, Marchillo K, Stamstad T et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1193-9.
11. Te Dorsthorst D, Verweij PE, Meis JF et al. Pharmacodynamics of BAL4815 a new azole antifungal in a mouse model of systemic infection. In: Abstracts of the Fourteenth European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, 2004. Abstract A-1874. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
12. Andes D, Marchillo K, Conkjin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-42.
13. Warn P, Sharp A, Denning D et al. In vivo activity of a new triazole BAL8557, the water-soluble prodrug of BAL4815, in a temporarily neutropenic murine model of disseminated Aspergillus flavus. In: Abstracts of the First Advances Against Aspergillosis Conference, San Francisco, CA, USA, 2004. Abstract 86, p. 105. Med Mycol 2005; 43 Suppl 1.